Melissa Loughney
Endocrinology, Diabetes & Metabolism · Washington, DCNPI 1588619936
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 117 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 19.8% — the pattern of someone who eats at a lot of different presentations.
Across 117 payments — averaging $27.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$641
- Dexcom, Inc.$403
- Pfizer$348
- AstraZeneca$210
- Lilly USA, LLC$205
- Tandem Diabetes Care, Inc.$192
- plus $1K from 25 others
What the payments were for
- Food & beverage$3,231100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 23 | $641 |
| Dexcom, Inc. | 10 | $403 |
| Pfizer | 15 | $348 |
| AstraZeneca(2 entities) | 4 | $210 |
| Lilly USA, LLC | 9 | $205 |
| Tandem Diabetes Care, Inc. | 4 | $192 |
| Biohaven Pharmaceutical Holding Company Ltd. | 7 | $160 |
| Novo Nordisk | 6 | $148 |
| Apollo Endosurgery US Inc | 1 | $141 |
| Boehringer Ingelheim | 5 | $117 |
| Exact Sciences | 4 | $102 |
| Sanofi-aventis U.S. LLC | 4 | $98 |
| GSK | 3 | $57 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $46 |
| Sanofi | 2 | $43 |
| Jazz Pharmaceuticals Inc. | 2 | $40 |
| Novartis | 1 | $25 |
| Ascendis Pharma Endocrinology Inc | 1 | $25 |
| Mallinckrodt Hospital Products Inc. | 1 | $23 |
| Astellas Pharma US Inc | 1 | $23 |
| Mallinckrodt Enterprises LLC | 1 | $20 |
| Insulet Corporation | 1 | $19 |
| Biohaven Pharmaceuticals, Inc. | 1 | $19 |
| Abbott | 1 | $19 |
| Phathom Pharmaceuticals, Inc. | 1 | $18 |
| Idorsia Pharmaceuticals US Inc | 1 | $18 |
| Corcept Therapeutics | 1 | $17 |
| Radius Health, Inc. | 1 | $17 |
| Amarin Pharma, Inc. | 1 | $14 |
| VBI Vaccine (delaware) Inc. | 1 | $13 |
| Bausch Health US, LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,231 in reported general payments places this provider in the 65th percentile of 44 endocrinology, diabetes & metabolism providers in District of Columbia.
See all endocrinology, diabetes & metabolism providers in District of Columbia →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 114 | $175,589 |
| OzempicSemaglutide | 71 | $124,804 |
| Tresiba Flextouch U-100Insulin Degludec | 55 | $35,341 |
| EliquisApixaban | 30 | $34,174 |
| ProliaDenosumab | 12 | $20,376 |
| MounjaroTirzepatide | 19 | $18,100 |
| JanuviaSitagliptin Phosphate | 14 | $15,332 |
| Lyumjev Kwikpen U-100Insulin Lispro-Aabc | 12 | $7,779 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 11 | $7,540 |
| SynthroidLevothyroxine Sodium | 58 | $6,986 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 49 | $5,768 |
| Candesartan Cilexetil | 21 | $2,872 |
| Humalog Kwikpen U-100Insulin Lispro | 12 | $2,869 |
| PaxlovidNirmatrelvir/Ritonavir | 17 | $2,858 |
| Atorvastatin Calcium | 194 | $2,637 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $205 | $193,689133 claims |
| Novo NordiskOzempic | $148 | $124,80471 claims |
| PfizerEliquis, Paxlovid | $348 | $37,03347 claims |
| AbbVieSynthroid | $641 | $6,98658 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 44 endocrinology, diabetes & metabolism providers in District of Columbia.
Other endocrinology, diabetes & metabolism in Washington
- Natasa Janicic-KahricWashington$121K
- Diala El-MaoucheWashington$99K
- Abbas MotazediWashington$31K
- Meeta SharmaWashington$25K
- Joseph VerbalisWashington$24K
- Mark SklarWashington$14K
- Sabyasachi SenWashington$12K
- Rui LuWashington$12K
- Qudsia HussainWashington$9K
- Jerold ShareWashington$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.